Antisense strategies for oncogene inactivation

Seminars in Oncology

Volumn 32, Issue 6, 2005, Pages 563-572

  Stein, C A ^a,b,c   Benimetskaya, Luba ^a   Mani, S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Scientific Advisory Board of Genta   (United States)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITAC; ALICAFORSEN; ALKYLATING AGENT; ALTEPLASE; ANTENNAPEDIA PROTEIN; ANTHRACYCLINE; ANTIMETABOLITE; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; CISPLATIN; DEFIBROTIDE; DENDRIMER; GYRASE INHIBITOR; HEPARIN; ISIS 104838; ISIS 2503; ISIS 3521; LIPID; LIPOFECTAMINE; LIPOFECTAMINE 2000; LIPOFECTIN; OBLIMERSEN; PEPTIDE DERIVATIVE; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; POLYAMINE; POLYETHYLENEIMINE; PORPHYRIN; RIBONUCLEASE H; STEROID; TRECOVIRSEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; BIOTECHNOLOGY; BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CELL TRANSPORT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVITY; FATIGUE; FEVER; GENE INACTIVATION; HUMAN; LIVER ENZYME BLOOD LEVEL; LYMPHOCYTOPENIA; MOLECULE; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TOXICITY; TREATMENT PLANNING; VOMITING;

EID: 28844454167     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.09.003     Document Type: Article

References (90)

1. M.L. Stephenson, P.C. Zamecnik Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide Proc Natl Acad Sci U S A 75 1978 285 288
2. R.J. Klasa, A.M. Gillum, R.E. Klem Oblimerson Bcl-2 Antisense Facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev 12 2002 193 212
3. N.M. Dean, R. McKay, T.P. Condon Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters J Biol Chem 269 1994 16416 16424
4. N.M. Dean, R. McKay Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides Proc Natl Acad Sci U S A 91 1994 11762 11766
5. T.J. McDonnell, N.M. Navone, P. Troncoso Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer J Urol 157 1997 569 574
6. J.J. Bauer, I.A. Sesterhenn, F.K. Mostofi Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer J Urol 156 1996 1511 1516
7. T. Miyashita, J.C. Reed Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 81 1993 151 157
8. S. Kamesaki, H. Kamesaki, T.J. Jorgensen Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair Cancer Res 53 1993 4251 4256
9. C.A. Stein, Y.-A. Cheng Antisense inhibition of gene expression V.T. DeVita S.A. Rosenberg S. Hellman Principles and Practice of Oncology 1997 Lippincott New York, NY 3059 3074
10. P.S. Eder, R.J. De Vine, J.M. Dagle Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma Antisense Res 1 1991 141 151
11. J.L. Vaerman, P. Moureau, F. Deldime Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides Blood 90 1997 331 339
12. P.G. Richardson, A.D. Elias, A. Krisnan Treatment of severe veno-occlusive disease with defibrotide Compassionate use results in response without significant toxicity in a high-risk population Blood 92 1998 737 744
13. K.J. Palmer, K.L. Goa Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders Drugs 1993 259 294
14. P.G. Richardson, C. Murakami, Z. Jin Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure response without significant toxicity in a high-risk population and factors predictive of outcome Blood 100 2002 4337 4343
15. M.M. Abecasis, J.P. Conceicao Silva, I. Ferreira Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation Bone Marrow Transplant 23 1999 843 846
16. S. Akhtar, S. Basu, E. Wickstrom Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes) Nucleic Acids Res 19 1991 5551 5559
17. J.L. Tonkinson, C.A. Stein Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells Nucleic Acids Res 22 1994 4268 4275
18. I. Lebedeva, L. Benimetskaya, C.A. Stein Cellular delivery of antisense oligonucleotides Eur J Pharmaceut Biopharmaceut 50 2000 101 119
19. J. Zabner, A.J. Fasbender, T. Moninger Cellular and molecular barries to gene transfer by a cationic lipid J Biol Chem 270 1995 18997 19007
20. L. Benimetskaya, G.B. Takle, M. Vilenchik Cationic porphyrins novel delivery vehicles for antisense oligodeoxynucleotides Nucleic Acids Res 26 1998 5310 5317
21. E.G. Marcusson, B. Bhat, M. Manoharan Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus Nucleic Acids Res 26 1998 2016 2023
22. O. Zelphati, F.C. Szoka Jr Mechanism of oligonucleotide release from cationic liposomes Proc Natl Acad Sci U S A 93 1996 11493 11498
23. C.C. Cunningham, J.T. Holmlund, R.S. Geary A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma Cancer 92 2001 1265 1271
24. B.R. Yacyshyn, W.Y. Chey, J. Goff ISIS 2302-CS9 Investigators Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-I antisense oligonucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut 51 2002 30 36
25. A. Webb, D. Cunningham, F. Cotter BCL-2 antisense therapy in patients with non-Hodgkin lymphoma Lancet 349 1997 1137 1141
26. B. Jansen, V. Wacheck, E. Heere-Ress Chemosensitisation of malignant melanoma by BCL2 antisense therapy Lancet 356 2000 1728 1733
27. T. Geiger, M. Muller, N.M. Dean Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice Anticancer Drug Des 13 1998 35 45
28. B.P. Monia First- and second-generation antisense inhibitors targeted to human c- raf kinase in vitro and in vivo studies Anticancer Drug Des 12 1997 327 339
29. L.M. Cowsert In vitro and in vivo activity of antisense inhibitors of ras Potential for clinical development Anticancer Drug Des 12 1997 359 371
30. M.Y. Chiang, H. Chan, M.A. Zounes Antisense oligonucleotides inhibit intercellular adhesion molecule I expression by two distinct mechanisms J Biol Chem 266 1991 18162 18171
31. A. Ziegler, G.H. Luedke, D. Fabbro Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence J Natl Cancer Inst 89 1997 1027 1036
32. B. Jansen, H. Schlagbauer-Wadl, B.D. Brown bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice Nat Med 4 1998 232 234
33. F.E. Cotter Antisense therapy of hematologic malignancies Semin Hematol 36 1999 9 14
34. H. Miayake, A. Tolcher, M.E. Gleave Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides J Natl Cancer Inst 92 2000 34 41
35. M.A. Guvakova, L.A. Yakubov, I. Vlodavsky Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix J Biol Chem 270 1995 2620 2627
36. S.M. Fennewald, R.F. Rando Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides J Biol Chem 270 1995 21718 21721
37. P. Rockwell, W.J. O'Connor, K. King Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides Proc Natl Acad Sci U S A 94 1997 6523 6528
38. J.P. Sheehan, H.-C. Lan Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex Blood 92 1998 1617 1625
39. J.P. Sheehan, T.M. Phan Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism Biochemistry 40 2001 4980 4989
40. W.-F. Cheung, J. van den Born, K. Kuhn Identification of the endothelial cell binding site for factor IX Proc Natl Acad Sci U S A 93 1996 11068 11073
41. R.Y. Walder, J.A. Walder Role of RNase H in hybrid-arrested translation by antisense oligonucleotides Proc Natl Acad Sci U S A 14 1988 6433 6451
42. J. Minshull, T. Hunt The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations Nucleic Acids Res 14 1986 6433 6451
43. N. Dias, P.E. Dheur, P.E. Nielsen Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation J Mol Biol 294 1999 403 416
44. S.A. Liebhaber, F.E. Cash, S.H. Shakin Translationally associated helix-destabilizing activity in rabbit reticulocyte lysate J Biol Chem 259 1984 15597 15602
45. B.P. Monia, E.A. Lesnik, C. Gonzalez Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression J Biol Chem 268 1993 14514 14522
46. S.K. Srinivasan, P. Iversen Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides J Clin Lab Anal 9 1995 129 137
47. R. Zhang, R.P. Iyer, D. Yu Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration J Pharmacol Exp Ther 278 1996 971 979
48. S. Agrawal, W. Tan, Q. Cai In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines Antisense Nucleic Acid Drug Dev 7 1997 245 249
49. S. Agraval In vivo pharmacokinetics of oligonucleotides C.A. Stein A.M. Krieg Applied Antisense Oligonucleotide Technology 1998 Wiley New York, NY 365 385
50. S. Agraval, R. Zhang Pharmacokinetics of phosphorothioate oligonucleotides and its novel analogs B. Weiss Antisense Oligonucleotides and Antisense RNA as Novel Pharmacological and Therapeutic Agents 1997 Boca Raton, FL, CRC Press 57 78
51. S. Agraval, J. Temsamani Comperative pharmacokinetics of antisense oligonucleotides S. Agraval Antisense Therapeutics 1996 Humana Press Totowa, NJ 247 270
52. A. Saikawa, T. Nomura, F. Yamashita Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system Pharm Res 13 1996 1438 1444
53. S. Nakajima, Y. Koshino, T. Nomura Intratumoral pharmacokinetics of oligonucleotides in a tissue-isolated tumor perfusion system Antisense Nucleic Acid Drug Dev 10 2000 105 110
54. J. Grindel, T.G. Musick, Z. Jiang Pharmacokinetics and metabolism of oligonucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion Antisense Nucleic Acid Drug Dev 8 1998 43 52
55. R. Zhang, Z. Lu, X. Zhang In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats Clin Chem 41 1995 836 843
56. R. Zhang, R.B. Diasio, Z. Lu Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficicency virus type-I Biomed Pharmacol 49 1995 929 939
57. Hanss B, Stein CA, Klotman PE: Cellular uptake and biodistribution of oligonucleotides, in Stein CA, Krieg AM (eds): Applied Antisense Oligonucleotide Technology. New York, NY, Wiley-Liss, pp 111-127
58. S. Agraval, J. Temsamani, W. Galbraith Pharmacokinetics of antisense oligonucleotides Clin Pharmacokinet 28 1995 7 16
59. J. Temsamani, J.Y. Tang, A.A. Padmapriya Pharmacokinetics biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice Antisense Res Dev 88 1993 7595 7599
60. J. Temsamani, A. Roskey, C. Chaix In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotides Antisense Nucleic Acid Drug Dev 7 1997 159 165
61. M. Rusckowski, T. Qu, A. Roskey Biodistribution and metabolism of a mixed-backbone oligonucleotide (GEM 231) following single and multiple doses administration in mice Antisense Nucleic Acid Drug Dev 10 2000 333 345
62. S.T. Crooke Potential roles of antisense technology in cancer chemotherapy Oncogene 19 2000 6651 6659
63. F.I. Raynaud, R.M. Orr, P.M. Goddard Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice J Pharmacol Exp Ther 281 1997 420 427
64. J.S. Waters, A. Webb, D. Cunningham Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma J Clin Oncol 18 2000 1812 1823
65. K.N. Chi, M.E. Gleave, R. Klasa A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer Clin Cancer Res 7 2001 3920 3927
66. M.J. Morris, W.P. Tong, C. Cordon-Cardo Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer Clin Cancer Res 8 2002 679 683
67. D.E. Lopes de Menezes, N. Hudon, N. McIntosh Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin Clin Cancer Res 6 2000 2891 2902
68. N.M. Dean, M. Butler, B.P. Monia Pharmacology of 2′-O-(2-methoxy) ethyl-modified antisense oligonucleotides S.T. Crooke Antisense Drug Technology Principles, Strategies and Applications 2001 Dekker New York, NY 319 338
69. K. Lea Sewell, R.S. Geary, B.F. Baker Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor J Pharmacol Exp Ther 303 2002 1334 1343
70. C.F. Bennett, M. Butler, P.D. Cook Antisense oligonucleotide-based therapeutics N.S. Templrton D.D. Lasic Gene Therapy 2000 Dekker New York, NY 305 332
71. A.A. Levin, S.P. Henry, D. Monteith Toxicity of antisense oligonucleotides S.T. Crooke Antisense Drug Technology 2001 Dekker New York, NY 201 267
72. R. Yu, H. Zhang, R.S. Geary Pharmacokinetics and pharmacodynamics of an antisense phosphorothiote oligonucleotide targeting Fas mRNA in mice J Pharmacol Exp Ther 296 2001 388 395
73. R.S. Geary, T.A. Watanabe, L. Truong Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats J Pharmacol Exp Ther 296 2001 890 897
74. J.C. Reed Bcl-2 and the regulation of programmed cell death J Cell Biol 124 1994 1 6
75. J.C. Reed Bcl-2 Prevention of apoptosis as a mechanism of drug resistance Hematol Oncol Clin North Am 9 1995 451 473
76. J.C. Reed, J.M. Jurgensmeier, S. Matsuyama Bcl-2 family proteins and mitochondria Biochim Biophys Acta 1366 1998 127 137
77. N. Dias, C.A. Stein Potencial roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides Eur J Pharmaceut Biopharmaceut 54 2002 263 269
78. G. Baffy, T. Miyashita, J.R. Williamson Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production J Biol Chem 268 1993 6511 6519
79. M.I. Walton, D. Whysong, P.M. O'Connor Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis Cancer Res 53 1993 1853 1861
80. T.C. Fisher, A.E. Milner, C.D. Gregory Bcl-2 modulation of apoptosis induced by anticancer drug resistance to thymidylate stress is independent of classical resistance pathways Cancer Res 53 1993 3321 3326
81. C. Tang, M.C. Willingham, J.C. Reed High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells Leukemia 8 1994 1960 1969
82. J.C. Reed, C. Stein, C. Subasinghe Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides Cancer Res 50 1990 6565 6570
83. S. Kitada, T. Miyashita, S. Tanaka Investigations of antisense oligonucleotides targeted against bcl-2 RNAs Antisense Res Dev 3 1993 157 169
84. S. Kitada, S. Takayama, K. De Riel Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression Antisense Res Dev 4 1994 71 79
85. F.E. Cotter, P. Johnson, P. Hall Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model Oncogene 9 1994 3049 3055
86. M.E. Gleave, H. Miayake, J. Goldie Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides Urology 54 1999 36 46
87. H. Miayake, A. Tolcher Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model Cancer Res 59 1999 4030 4034
88. F.E. Cotter, M. Corbo, F. Raynaud Bcl-2 antisense therapy in lymphoma In vitro and in vivo mechanisms, efficacy, pharmacokinetics and toxicity studies Ann Oncol 7 1996 32
89. J.M. Kirkwood, A.Y. Bedikian, M.J. Millward Long term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bc1-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma Proc Am Soc Clin Oncol 23 2005 711s (abstr)
90. Genta press release, Friday, May 13, 2005